BRAF and melanoma: Membership scores were calculated on a cell-by-cell basis for signatures (Supplementary Data 24-25) that have been reported for treatment-naïve human melanoma biopsies55 (including patients with both primary and metastatic human melanomas); patient-derived xenografts grown in immune deficient mice and subjected to Braf-inhibitor treatment22; melanoma cell lines (commercially available and stepwise CRISPR-edited)19,56; and other mouse melanoma models (NrasQ61K/+Ink4aΔ/Δ, Braf CA/+PtenΔ/Δ18, and stepwise CRISPR-edited56).